Nirmatrelvir-ritonavir for COVID-19.
作者信息
McDonald Emily G, Lee Todd C
机构信息
Clinical Practice Assessment Unit (McDonald, Lee), and Divisions of Internal Medicine (McDonald) and Infectious Diseases (Lee), Department of Medicine, McGill University Health Centre, Montréal, Que.
出版信息
CMAJ. 2022 Feb 14;194(6):E218. doi: 10.1503/cmaj.220081. Epub 2022 Feb 3.
Abstract
摘要
相似文献
1
Nirmatrelvir-ritonavir for COVID-19.用于治疗新冠肺炎的奈玛特韦片/利托那韦片组合包装
CMAJ. 2022 Feb 14;194(6):E218. doi: 10.1503/cmaj.220081. Epub 2022 Feb 3.
2
Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management.在新冠病毒疾病管理中使用利托那韦增强型PF-07321332时需谨慎。
Lancet. 2022 Jan 1;399(10319):21-22. doi: 10.1016/S0140-6736(21)02657-X.
3
Audio Interview: A New Antiviral against Covid-19.音频访谈：一种新型抗新冠病毒药物
N Engl J Med. 2022 Feb 17;386(7):e25. doi: 10.1056/NEJMe2202349.
4
Bad news for Paxlovid? Resistance may be coming.对帕罗韦德（Paxlovid）来说是个坏消息？耐药性可能出现了。
Science. 2022 Jul 8;377(6602):138-139. doi: 10.1126/science.add8037. Epub 2022 Jul 7.
5
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.奈玛特韦片/利托那韦片组合包装口服药用于伴有进展为重症高风险因素的 COVID-19 门诊患者。
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
6
From Positive to Negative to Positive Again-The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid.从阳性到阴性再到阳性——服用帕罗韦德的部分新冠患者病情反弹之谜
JAMA. 2022 Jun 28;327(24):2380-2382. doi: 10.1001/jama.2022.9925.
7
Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment.奈玛特韦-利托那韦治疗后新型冠状病毒2型感染的反弹
N Engl J Med. 2022 Sep 15;387(11):1045-1047. doi: 10.1056/NEJMc2206449. Epub 2022 Sep 7.
8
Paxlovid for treatment of COVID-19.用于治疗新冠病毒病的帕罗韦德
Med Lett Drugs Ther. 2022 Jan 24;64(1642):9-10.
9
An oral SARS-CoV-2 M inhibitor clinical candidate for the treatment of COVID-19.一种用于治疗 COVID-19 的口服 SARS-CoV-2 M 抑制剂临床候选药物。
Science. 2021 Dec 24;374(6575):1586-1593. doi: 10.1126/science.abl4784. Epub 2021 Nov 2.
10
Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19.奈玛特韦-利托那韦与新冠病毒感染中的病毒载量反弹
N Engl J Med. 2022 Sep 15;387(11):1047-1049. doi: 10.1056/NEJMc2205944. Epub 2022 Sep 7.
引用本文的文献
1
Real-world analysis of safety, tolerability, and adherence to nirmatrelvir-ritonavir (paxlovid) in primary care COVID-19 outpatients.真实世界中，在基层医疗机构的 COVID-19 门诊患者中使用奈玛特韦/利托那韦（帕罗韦德）的安全性、耐受性和用药依从性分析。
Sci Rep. 2024 Oct 21;14(1):24750. doi: 10.1038/s41598-024-75192-9.
2
Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (M).靶向严重急性呼吸综合征冠状病毒2（SARS-CoV-2）主要蛋白酶（M）的抑制剂的研究进展
ACS Omega. 2024 Aug 2;9(32):34196-34219. doi: 10.1021/acsomega.4c03023. eCollection 2024 Aug 13.
3
Simultaneous measurement of COVID-19 treatment drugs (nirmatrelvir and ritonavir) in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study.采用超高效液相色谱-串联质谱法同时测定大鼠血浆中新冠治疗药物（奈玛特韦和利托那韦）及其在药代动力学研究中的应用
Heliyon. 2024 May 30;10(11):e32187. doi: 10.1016/j.heliyon.2024.e32187. eCollection 2024 Jun 15.
4
Low-Data Drug Design with Few-Shot Generative Domain Adaptation.基于少样本生成域适应的低数据药物设计
Bioengineering (Basel). 2023 Sep 21;10(9):1104. doi: 10.3390/bioengineering10091104.
5
The "outsized" role of the I-helix kink in human Cytochrome P450s.I型螺旋扭结在人类细胞色素P450中的“巨大”作用。
Clin Transl Med. 2023 Sep;13(9):e1378. doi: 10.1002/ctm2.1378.
6
Advances and challenges in using nirmatrelvir and its derivatives against SARS-CoV-2 infection.使用奈玛特韦及其衍生物对抗新型冠状病毒感染的进展与挑战。
J Pharm Anal. 2023 Mar;13(3):255-261. doi: 10.1016/j.jpha.2022.10.005. Epub 2022 Nov 2.
7
Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal.超越疫苗：一瞥基于小分子和肽的抗 COVID-19 武器库。
J Biomed Sci. 2022 Sep 6;29(1):65. doi: 10.1186/s12929-022-00847-6.
8
Real-world effectiveness of granules-based treatment on patients infected with the SARS-CoV-2 Omicron variants BA.2 combined with high-risk factors: A cohort study.基于颗粒剂的治疗对感染严重急性呼吸综合征冠状病毒2奥密克戎变种BA.2并伴有高危因素患者的真实世界疗效：一项队列研究。
Front Pharmacol. 2022 Aug 16;13:978979. doi: 10.3389/fphar.2022.978979. eCollection 2022.
9
COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed.COVID-19 与抗癫痫药物：尼马曲韦/利托那韦合并用药时的实践指导方法。
Eur J Clin Pharmacol. 2022 Oct;78(10):1697-1701. doi: 10.1007/s00228-022-03370-7. Epub 2022 Aug 5.
10
Renalism.肾本位主义
CMAJ. 2022 Aug 2;194(29):E1040. doi: 10.1503/cmaj.146430-l.
本文引用的文献
1
Outpatient Therapies for COVID-19: How Do We Choose?新冠病毒病的门诊治疗：我们如何选择？
Open Forum Infect Dis. 2022 Jan 19;9(3):ofac008. doi: 10.1093/ofid/ofac008. eCollection 2022 Mar.
Zotero 插件